Heartburn treatment in primary care: randomised, double blind study for 8 weeks - Wikidata - awgldk - TriplyDB

Heartburn treatment in primary care: randomised, double blind study for 8 weeks

Heartburn treatment in primary care: randomised, double blind study for 8 weeks

http://www.wikidata.org/entity/Q33648493

about

Medical treatments in the short term management of reflux oesophagitis Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease Initial management strategies for dyspepsia Medical treatments in the short term management of reflux oesophagitis Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease Initial management strategies for dyspepsia Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease Should peri-gastrectomy gastric acidity be our focus among gastric cancer patients?Heartburn treatment in primary care. Prescribing omeprazole would conflict with desire to control prescribing costs.An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Canadian Dyspepsia Working Group.Management of gastro-oesophageal reflux disease in general practice Endoscopy-negative reflux disease.Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease.The clinical and economic impact of competing management strategies for gastro-oesophageal reflux disease.Management of uninvestigated dyspepsia: review and commentary.Short-term treatment of gastroesophageal reflux disease.Review article: gastric acidity--comparison of esomeprazole with other proton pump inhibitors.Goals of therapy and guidelines for treatment success in symptomatic gastroesophageal reflux disease patients.Long-term safety of proton pump inhibitors: risks of gastric neoplasia and infections.Assessment of reflux symptom severity: methodological options and their attributes.Multimodal pain stimulations in patients with grade B oesophagitis Systematic review: the effect of Helicobacter pylori and its eradication on gastro-oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis.Gastric juice: a barrier against infectious diseases.Gastroesophageal reflux and gastric emptying, revisited.Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas.Ambulatory reflux monitoring in GERD--which test should be performed and should therapy be stopped?Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpoint.Reflux inhibitor drugs: an emerging novel therapy for gastroesophageal reflux disease.Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies.Cisapride: what can we learn from the rise and fall of a prokinetic?Prokinetic drug utility in the treatment of gastroesophageal reflux esophagitis: a systematic review of randomized controlled trials.Randomised clinical trial: a comparison between a GerdQ-based algorithm and an endoscopy-based approach for the diagnosis and initial treatment of GERD.PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis.Long-term outcome of Nissen fundoplication in non-erosive and erosive gastro-oesophageal reflux disease.Determination of ReQuest-based symptom thresholds to define symptom relief in GERD clinical studies.Does Helicobacter pylori infection influence response rate or speed of symptom control in patients with gastroesophageal reflux disease treated with rabeprazole?Heartburn-dominant, uninvestigated dyspepsia: a comparison of 'PPI-start' and 'H2-RA-start' management strategies in primary care--the CADET-HR Study.The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole.How well is the clinical importance of study results reported? An assessment of randomized controlled trials.Helicobacter pylori infection and long term proton pump inhibitor therapy.

P2860

Q24234225-C04A125E-50E8-4F6C-8A37-2506F8CD84E1 Q24236493-14ED6810-F98F-44BB-821A-335E35973FD6 Q24240744-E09A3148-BB6F-48CE-9964-1B14962F1F9C Q24245220-AC335930-8ADD-42B7-B7C3-4E2467FAFFB9 Q24245237-5D3A781A-DB2D-4357-9DEF-830CDF0E46B1 Q24245815-636B9C74-479D-4C56-A37F-6F64A7FC8157 Q24246801-B760A624-75AE-4072-A3D2-3E0BF11EFC3F Q33735357-D6BCFA80-B884-4A55-B24C-760E9E494504 Q33801030-B308A7DC-97A4-4782-8A10-9CD3D0778EA5 Q33952311-76BCA914-C80D-4607-82F0-9DEFD9C3B22C Q34131661-8DF9568A-D915-41ED-9310-57CF9235FF27 Q34251261-02B016EC-E73C-4B56-B2DC-8A294A339E04 Q34424848-1674B689-8E75-4BC6-AB5A-09E7B589EE33 Q34541695-48BD0C4E-77A6-44C6-A9E0-98D0AA2A8D21 Q34601069-72087A28-04F7-4F86-980C-FFF320B12BA8 Q34742191-943B5B19-C03E-4A91-AC90-CECBF4EDE3C5 Q35076640-612E9127-89E9-4DC2-B22A-1C9A96338B9E Q35087982-7DE3C43C-1579-4B46-90CD-7F1381FC6103 Q35194532-FB1B3F43-5580-4382-8102-3B62B0B415D9 Q35745038-E007DD4F-61EB-4B23-B1F9-FE89D48F8F74 Q35760744-F3E9775D-6DC0-4B00-8C4B-F4A7924DE7A1 Q35893211-4213989C-1CBC-4786-A300-B8D8D96F9247 Q36023592-888E3A20-E133-4174-B48E-1C9FABBD28AC Q36137472-629EF52D-9838-4A15-A27C-674A44B51697 Q36376528-AB9C335D-6973-462A-B16F-8C2272562E0B Q36765136-2B8009AF-4ED6-4694-8CE0-28D36FDED765 Q37650556-CDCD6C05-14BB-4AD3-8D41-847162A22112 Q37733709-6206F829-E2C4-4D89-A23A-43BB5E9E78BB Q37775998-F23009EE-9ACF-449B-840C-0EC3BF4E70D6 Q37880285-E1C8719A-5C8E-4FC5-ACCF-5D28392BF030 Q37889655-CC115607-0A2A-41AD-B691-DB791CEFD38E Q39249108-50C4E61A-787B-4659-84E6-E5C4030E4AB2 Q39252347-E1BCB7E1-EE17-45BE-B2E6-C3A1B5219F03 Q39285853-A3247565-FD84-4FAE-96C9-4C1A0E450C4F Q39335662-3E582C96-7DDE-4EEB-8587-DE2BBF7AFFA5 Q39345800-90D6CA77-ABDE-439A-B373-70C5200ECC48 Q39367299-01C9B5B9-2FCC-404B-B84A-FFA2B6EDC1E0 Q39377527-94ED48D2-5A9F-4B12-8FD5-BD13F7E966A6 Q39434130-4FE2097F-D09B-423F-BB57-4BDA2865B0B5 Q42003652-79A7F98A-44B9-47A2-95D2-58264809FC99

P2860

Heartburn treatment in primary care: randomised, double blind study for 8 weeks

http://www.wikidata.org/entity/Q33648493

description

1999 nî lūn-bûn

@nan

1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

1999 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

name

Heartburn treatment in primary care: randomised, double blind study for 8 weeks

@ast

Heartburn treatment in primary care: randomised, double blind study for 8 weeks

@en

type

label

Heartburn treatment in primary care: randomised, double blind study for 8 weeks

@ast

Heartburn treatment in primary care: randomised, double blind study for 8 weeks

@en

prefLabel

Heartburn treatment in primary care: randomised, double blind study for 8 weeks

@ast

Heartburn treatment in primary care: randomised, double blind study for 8 weeks

@en

P1433

Q33648493-EF1E560D-22B1-4721-BDC4-9EAF7EEE6B9D

P1476

Q33648493-80161978-E030-4B9F-8D0C-2B66B43791C4

P2093

Q33648493-1B220744-5B46-4EB1-9FC1-7309EBD43921

Q33648493-95219232-0606-4CB2-A68F-A671CA7E5F06

Q33648493-BCBE53BD-846E-48CD-9D4C-A06CBB3EA720

Q33648493-C00FEC35-8457-4DD0-8826-2A1D96444805

Q33648493-DE90F102-0D81-4322-9EE9-B994FB76F645

Q33648493-E661215A-E33F-47C2-AA82-0B66C337BEF6

P2860

Q33648493-1CA1B736-ADB7-4626-A47F-10D9C3EF9C36

Q33648493-3FC8E7E5-3C00-462E-80A1-AD29BDC0801F

Q33648493-56ECC73C-E043-43C4-BE76-6732C7B437F9

Q33648493-6261845B-FDBA-4165-AE9A-1FFC2EEFBB13

Q33648493-6F82EFC5-3991-4303-92D2-4FC363414D38

Q33648493-705C4B97-4446-419F-8105-D3F4F386A4EC

Q33648493-7B1854D6-5E26-473C-9C06-1FFCB3E2E04E

Q33648493-80007E34-BC6D-4C4B-8ADF-465AA436D857

Q33648493-82A89C46-8501-4B1A-BA52-9E959BB710A3

Q33648493-94786C12-5CB3-45E6-9EEE-B7C5BDD5726D

P304

Q33648493-52FE5EC0-A42E-4DFB-BBCB-000BAF0FD48B

P31

Q33648493-EF57CFCB-70C1-4E43-83F4-29B9EFE991DF

P356

Q33648493-3AABF3C2-7E8E-4651-A108-AEC73AE2E9F2

P407

Q33648493-DF6FE9BA-9A8D-4FB8-8CC6-685802C6253C

P433

Q33648493-90F2E058-E313-4795-8D95-0E589A76FDD4

P478

Q33648493-497F4C7A-E813-4AB3-9EE2-5EE7FCAF36A7

P50

Q33648493-101247F9-F835-44CF-AB17-BE9250116C61

Q33648493-BE38C043-A96B-4C77-8D8E-27D32B21580E

P577

Q33648493-A33FA553-B00D-43A1-BDE4-143CB14AEEA9

P5875

Q33648493-6B3B4BDC-E293-4DAE-89F4-7B93F484B388

P698

Q33648493-D6C20D0B-E8E5-4F35-B0F3-B6B098E9DC57

P932

Q33648493-74F0D744-EF80-4EC4-8E8F-7D92DB38B936

P356

BMJ.319.7209.550

P1433

P1476

Heartburn treatment in primary care: randomised, double blind study for 8 weeks

@en

P2093

A Hyggen

http://www.w3.org/2001/XMLSchema#string

P H Madsen

http://www.w3.org/2001/XMLSchema#string

P Mowinckel

http://www.w3.org/2001/XMLSchema#string

P O Walle

http://www.w3.org/2001/XMLSchema#string

T Bernklev

http://www.w3.org/2001/XMLSchema#string

T Schulz

http://www.w3.org/2001/XMLSchema#string

P2860

The effect of cisapride in maintaining symptomatic remission in patients with gastro-oesophageal reflux disease.

Dyspepsia in England and Scotland

Effect of cisapride on delayed gastric emptying in gastro-oesophageal reflux disease

Cisapride restores the decreased lower oesophageal sphincter pressure in reflux patients.

Effect of cisapride on postprandial gastro-oesophageal reflux.

Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group.

Cisapride 20 mg b.i.d. provides symptomatic relief of heartburn and related symptoms of chronic mild to moderate gastroesophageal reflux disease. CIS-USA-52 Investigator Group.

Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice.

Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Results of a Scandinavian multicentre trial.

Double-blind comparison of cisapride and cimetidine in treatment of reflux esophagitis.

P304

550-553

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BMJ.319.7209.550

http://www.w3.org/2001/XMLSchema#string

P407

P433

7209

http://www.w3.org/2001/XMLSchema#string

P478

319

http://www.w3.org/2001/XMLSchema#string

P50

Jan Gunnar Hatlebakk

P577

1999-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12835893

http://www.w3.org/2001/XMLSchema#string

P698

10463897

http://www.w3.org/2001/XMLSchema#string

P932

28208

http://www.w3.org/2001/XMLSchema#string